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ABSTRACT 
Administration of PGF 2IX (0.2-6.4 J.lg) into the lateral cerebral ventricle (i.c.v.) induced dose-
dependent increases in blood pressure , heart rate and body temperature in urethane-anaesthetised 
rats, but had no effect on these parameters when the same dose range was administered intravenously. 
Peripheral pretreatment with sodium meclofenamate (50 mg/kg s.c.) sltifted all the dose-response 
curves for PGF 2IX (i.c.v.) to the left, but indomethacin (50 mg/kg s.c.) did not significantly affect 
those changes. Central pretreatment with sodiurn meclofenamate or indomethacin (1.25 mg per 
rat i.c.v.) failed to modify significantly the effects of centrally administered PGF 2IX' 
The results support previous suggestions that PGF 2IX may participate in the central control of 
the cardiovascular and thermoregulatory systems, and also suggest that there may be differences 
in the sites and/or modes of action between sodiurn meclofenamate and indomethacin. 
INTRODUCTION 
Prostagiandin F 2 IX (PGF 2 IX) is one of the most common prostaglandin types in the central nervous 
system (2,3), but its possible physiological functions in the brain are not known. Some investigators 
have suggested that prostaglandins may be involved in the central control of thermoregulatory and 
cardiovascular systems (2). Prostaglandins of the E-type are highly active pyrogenic agents in the 
brain (4), whereas PGF 2 IX seems to be the most potent prostaglandin affecting the central mechanisms 
of cardiovascular control (5). Although it has been sltown that intracerebroventricular administrations 
of PGF 2IX increase blood pressure and heart rate in anaesthetised rats (6), no dose-response relation-
ships have been establislted. 
In the present study various doses of PGF 2 IX were administered into the lateral cerebral ventricle 
of urethane-anaesthetised rats in order to obtain complete simultaneous dose -response curves for 
blood pressure , heart rate and body temperature. Since sodium meclofenamate antagonises the effects 
of exogenous PGF2IX in peripheral tissues (7, 8, 9), it seemed worthwhile to ex amine the influence 
of this agent on the central effects of PGF 2IX' For comparison, the effects of indomethacin, which 
is as effective an inhibitor of prostaglandin synthesis as sodium meclofenamate (10), were also studied. 
MATERIALS AND METHODS 
Sprague-Dawley rats (240-340 g) of both sexes were used, although in each type of experiment 
all control and experimental animals were of the same sex. The rats were accommodated to standard 
ambient conditions for at least one week before the experiments. The lights were on from 7 a.m. 
to 7 p.m. and the room was completely dark during the remaining 12 hours. The temperature was 
kept at 22 oe and the relative humidity at 40 %. The rats received standard rat pellets (Hankkija 
Oy, Helsinki) and tap water ud libitum. 
! A preliminary report of this work was presented at XXXI Meeting of the Scandinavian PharmacoIogicaI Society. 
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The rats were anaesthetised with urethane (1.5 glkg Lp.). The trachea was cannulated with a 
polyethylene tube and the rats were allowed to breathe spontaneously. The mean arterial blood 
pressure was measured from the left femoral artery by means of apressure transducer (Harvard 
apparatus 377). The heart rate was calculated from the pulse waves, the left femoral vein was 
cannulated for intravenous injections. The rats were mounted in a stereotaxic instrument and tilted 
caudally so that the body formed an angle of 10 degrees with the horizontal plane. An injection 
needle was introduced into the right lateral ventricle of the brain. A polyethylene catheter, filled with 
the drug or control solution to be infused, was then attached to the needle and the desired amount of 
the solution was allowed to flow slowly by virtue of hydrostatic pressure . The infusion was stopped 
by closing the upper end of the catheter. The proper position of the needle tip was ascertained at the 
end of each experiment by an injection of dye (methylene blue) into the cerebral ventricle. 
The body temperature was measured rectally with a temperature recorder (ELLAB instruments, 
type Z8, Copenhagen), a probe being introduced 5 cm into the rectum. A 60 W heating lamp was 
placed 20 cm above the rat. Experiments on control rats showed that this distance for the heating 
lamp was adequate to keep the body temperature at 35.3 °c - 36.7 °c in an ambient temperature 
of 22°C which was kept constant automatically by air conditioning. 
Administration of drugs 
The stock solution of PGF2a, 1 mg/mI (Astra), was diluted with a modified Krebs-Ringer bicar-
bonate buffer (NaCl 117.0 mM, KCl 2.95 mM, CaC12 1.44 mM, KH2 P04 0.01 mM, MgS04 • 7 H2 0 
1.12 mM, and NaHC03 23.6 mM) to simulate the concentrations found in the cerebrospinal fluid 
(11). For intravenous administrations the stock solution of PGF2a was diluted with 0.9 % (w/v) 
NaCl (saline). The intracerebroventricular injections of PGFw were given in a volume of 5 I.d each, 
with the exception of the largest dose which was given in a volume of 10 pI. Intravenously the various 
doses of PGF2a were injected in a volume of 0.1 mI each. The control animals received the same 
volume of the corresponding vehicle in each case. Increasing doses of PGF 2a were injected intra-
cerebroventricularly at 15 min intervals in order to obtain a cumulative dose-response curve. This 
interval was chosen because the maximum pressor effect of PGF2a was reached within 15 min after 
the Lc.v. injections. The intravenous injections were also repeated at 15 min intervals to make sure 
that the effects induced by cent rally administered PGF 2 a were not due to leakage of the drug into 
the peripheral circulation. 
Indomethacin (Orion Oy, Helsinki) was dissolved in 0.05 N NaOH and sodium meclofenamate 
monohydrate (Parke, Davis & Co.) in saline. The influence of peripheral pretreatment with 
indomethacin or sodium meclofenamate on the central effects of PGF2a was studied by injecting 
the drugs subcutaneously, 50 mg/kg, two hours before commencement of the administration of 
cumulative doses of PGFw ' The effect of central pretreatment was studied by infusing indomethacin 
or sodium meclofenamate Lc.v. at the dose of 1.25 mg in a volume of 5 td 20 min before com-
mencement of the admininistration of cumulative doses of PGF2a. In each case the control animals 
received the same volumes of the corresponding vehicle at the same pH as the drug solution. 
The Student's t-test was used to calculate the statistical significance of the differences between 
the control and experimental groups. 
RESULTS 
I Effects of prostagIandin F 2 a in non-pretreated rats 
Effect of PGF2a on blood pressure (Fig. 1) 
Intracerebroventricular injection of PGF2a at the doses of 0.2--6.4 pg/rat increased the blood 
pressure in a dose-related manner, the maximum effect, about 20 mm Hg being reached with a dose 
of 3.2 pg/rat. Intravenously, PGF 2 a had no significant effect on blood pressure at the doses of 
0.2--6.4 pg/rat. 
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Fig. I. Influence of PGF2a on blood pressure in urethane-anaesthetised maie rats. Cumulative doses of PGF2a 
were administered intracerebroventricularly (-) or intravenously (~) at 15-min intervaIs_ Each 
dose is indicated on the abscissa_ The blood pressure level before commencement of the administration of 
PGF2a or solvent i.c.v. (0--0) was 100 ± 20 mm Hg in the controlgroup, 95 ±20 mm Hg in the PGF2a 
i.c_v. group, and 80 ± 10 mm Hg in the PGF 20! i.v. group. The differences in baseline levels between the 
groups are not statisticaIly significant_ The rises in blood pressure as compared with the control vaIues 
at doses of 0_2-0.4 !J.g/rat and 3_2-6_4 !J.g/rat tc_v_ were significant at the p < 0_05 level. The results 
obtained with PGF20! i_v. did not differ significantly from the control vaIues. VerticaI bars indicate s.e. 
mean. Each group comprised 6 rats. 
Ellect 01 PGF2 a on heart rate (Fig. 2) 
When adrninistered intracerebroventricularly, PGF2a doses ofO.2-6.4 J.l.g/rat induced a substantiaI 
tachycardic effect, which becarne observable 2-5 rnin after the injections. The maximum change, 
achieved with the highest dose, was almost 200 beats/rnin. Intravenously administered PGF 20! had 
no significant effect on the heart rate at the doses used. 
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Fig. 2. Influence of PGF 20! on heart rate in urethane-anaesthetised maIe rats. Cumulative doses of PGF 20! were 
administered i.c.v. (_) or i.v. (6----.0) at 15-min intervaIs. Each dose is indicated on the abscissa. 
The heart rate before commencement of the administration of PGF20! or solvent i.c.v. (0--0) was 350 ± 
30 beats/min in the control glOup, 340 ± 20 beats/min in the PGF 20! i.c.v. group, and 360 ± 20 beats/min 
in the PGF 20! i.v. group. The differences in baseline levels between the groups are not statisticaIly 
significant. The tachycardic effects of PGF 20! (0.2-6.4 Ilg/rat i.c.v.) were significant as compared with 
the control vaIues at the p < 0.05-0.001 level. The results obtained with PGF 2 0! i.v. did not differ sig-
nificantly from the control vaIues. VerticaI bars indicate s.e. mean. Each group comprised 6 rats. 
Ellect 01 PGF2 0! on body temperature (Fig_ 3) 
Centra11y administered PGF2 0! had a dose-dependent hyperthermie effeet, so that after the highest 
dose the average inerease in body temperature was about 2_6°C.With intravenous injeetions PGF 2 0! 
had no statistiea11y signifieant effeet on body temperature_ 
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Fig. 3. Influenee of PGF 2<X on body temperature in urethane-anaesthetised male rats. Cumulative doses of PGF 2<X 
were administered i.e.v. ( ___ ) or i.v. (A---.O) at 15-min intervals. Eaeh dose is indieated on the abscissa. 
The hyperthermie effeet of PGF2<x i.e.v. was signifieant as eompared with the eontrol i.e.v. values (0----0) 
at the p < 0.05 -0.001 level at doses of 1.6-6.4 IJ.g/rat. The results obtained with PGF 2<X i.v. did not differ 
signifieantly from the control values. The differenees between the i.e.v. and i.v. groups were signifieant at 
the p < 0.05-0.001 level at the doses of 0.2-6.4 IJ.g/rat. Vertieal bars indicate s.e. mean. Eaeh group 
eomprised 6 rats, exeept in the first i.e.v. dose (5 rats). 
Interrelationship between PGF2<X-induced changes in blood pressure, heart rate and body temperature 
The time·response effects on blood pressure, heart rate and body temperature of the smallest 
dose of PGF 2 <x, 0.2 I1g/rat i.c.v. are demonstrated in Fig. 4. The rise in both blood pressure and 
heart rate was greater than that in body temperature, and preceded it in time. 
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Fig.4. Time·response effects of PGF 2a on blood pressure (-----), heart rate (0---0) and body temperature 
(---..) after the lust administration of the dose of 0.2 /Jg/rat i.c.v. The number of rats was 6. Vertical 
bars indicate s.e. mean. 
11 Effects of sodium mecIofenamate and indomethacin 
After subcutaneous administrations neither sodium mec10fenamate nor indomethacin had any 
significant effects of their own on the baseline vaIues for blood pressure, heart rate or body tem· 
perature. Intracerebroventricularly administered sodium meclofenamate induced a slight increase 
in heart rate and a fall in body temperature (Table 1). 
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Table 1. Baseline values for blood pressure (B.P.), heart rate (H.R.) and body temperature (B.T.) in indomethacin 
and sodium medofenamate pretreated rats and their contral groups irnmediately before commencement of PGF 2a 
administrations Lc.v. The values represent means ± SD means. Each group comprised 6 rats, except for the control 
graup for indomethacin Lc.v. (5 rats) and that for sodium medofenamate s.c. (4 rats). 
B.P. H.R. B.T. 
Pretreatment (mmHg) (beats/min) (C) 
A. Subcutaneously 1 
saline 95 ± 15 340 ± 30 36.0 ± 0.0 
sodium medofenamate (50 mg/kg) 90 ± 10 320 ± 10 36.0 ± 0.3 
vehide 90 ±20 390 ± 20 36.7±0.2 
indomethacin (50 mg/kg) 90 ± 10 370 ± 30 36.7 ± 0.2 
B. Intracerebroventricularly2 
saline 85 ± 10 340 ± 20 37.0±0.1 
sodium medofenamate (1.25 mg/kg) 85 ± 10 400 ± 10* 36.0 ± 0.2** 
vehide 90 ± 20 310 ± 30 36.0 ± 0.3 
indomethacin (1.25 mg/rat) 85 ± 15 360 ± 20 36.0 ± 0.3 
1 Male rats used. 2 Female rats used. * p < 0.05 vs. contral group. ** p < 0.01 vs. control group. 
III Effects of intracerebroventricular PGF 2 a in sodium mecIofenamate and indomethacin pretreatedrats 
Effects of sodium meclofenamate pretreatment 
Peripheral pretreatrnent with sodiurn mec10fenarnate (50 mg/kg s.e.) potentiated the inerease in 
blood pressure indueed by intraeerebroventrieular PGF 2a' shifting the dose-response eurve of PGF 2a 
to the left (Fig. 5). A sirnilar effeet was noted upon the taehyeardic and hyperthermie actions of 
cent rally administered PGF 2a (Figs. 6 and 7). 
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Fig. 5. Effect of PGF2a i.c.v. on 
blood pressure in sodium medo-
fenamate (_) and saline (0---0) 
pretreated male rats. Sodium medo· 
fenamate (50 mg/kg) or saline was 
injected subcutaneously two hours 
before commencement of the ad· 
ministration of cumulative doses of 
PGF2a i.c.v. The differences betw~en 
the sodium medofenamate and saline 
groups were significant at the p <0.05 
level at PGF 2a doses of 0.2-0.8 Ilg/ 
rat. Vertical bars indicate s.e. Both 
PG F2c< (f-I 9 I ra t ) graups comprised 6 rats. 
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Fig. 6. Effect of PGF 2(1 i.c.v. on 
heart rate in sodium meclo-
fenamate (-) and saline (0-0) 
pretreated male rats. Sodium 
meclofenamate (50 mg/kg) or 
saline was injected subcutaneously 
two hours before commencement 
of the administration of cumu-
lative doses of PGF 2il i.c.v. 
The differences between the 
sodium meclofenamate and saline 
groups were significant at the p < 
0.05- 0.01 level at PGF2Q doses 
of 0.2- 0.8 j.tg/rat. Vertical bars 
indicate s.e. means. Both groups 
comprised 6 rats. 
Fig. 7. Effect of PGF2Q i.c.v. on 
body temperature in sodium 
meclofenamate ( ....... ) and saline 
(0-0) pretreated male rats. 
Sodium meclofenamate (50 mg/ 
leg) or saline was injected sub· 
cutaneously two hours before 
commencement of the admi-
nistration of cumulative doses of 
PGF2Q i.c.v. The differences 
between the sodium meclo-
fenamate and saline groups were 
significant at the p < 0.05 level at 
a dose of 1.6 j.tg/rat, at the 
p < 0.01 level at doses of 0.8 and 
6.4 J,tg/rat and the p <0.001 level 
at doses of 0.2-0.4 and 3.2 j.tg/rat. 
The sodium meclofenamate pre-
treated group comprised 6 rats 
and the control group 4. Vertical 
bars indicate s.e. means. 
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Central pretreatment with sodium mec1ofenamate, 1.25 mg/rat i.c.v., 20 min before commencement 
of the administration of cumulative doses of PGF20i i.c.v., did not significantly influence the hyper-
tensive, tachycardic or hyperthermic effects ofPGF20i (results not shown). 
Effect ofindomethacin pretreament 
Indomethacin did not influence significantly any of the dose-response curves for PGF 201 when 
given peripherally (50 mg/kg s.c. two hours before commencement of the administration of PGF2 0' 
i.c.v.), or centrally (1.25 mg/rat i.c.v. 20 min before commencement of the administration of PGF 20' 
i.c.v.). (Results not shown.) 
DISCUSSION 
PGF20i i.c.v. raised the blood pressure,heart rate and bodytemperature ofurethane-anaesthetised 
rats in a dose-related mann er. These effects were not due to any leakage of the drug into the periphery, 
but to an action upon the central nervous systems, since the same doses of PGF20i did not affect 
these parameters upon intravenous administration. This assumption is supported by the fact that 
PGF2 0' raised the blood pressure and heart rate upon infusion into the vertebral artery in chlora 
lose-anaesthetised dogs, but not after administration of the same doses intravenously (5). Infusion of 
PGF20i into the vertebral artery of conscious dogs raised the blood pressure, but did not affect the 
heart rate (12). In agreement with the present results it has been reported that administration of 
PGF 201 at the doses of 1 or 10 /lg per rat into the cerebral ventric1e increases the blood pressure and 
heart rate of urethane-anaesthetised rats (6). The hyperthermic effect of centrally administered PGF 20' 
has previously been demonstrated in conscious rabbits and cats (13) and also in chickens and rats 
(15). Since PGF 2 0' is present in abundance in the brain (2,3) and exerts strong dose-dependent 
central effects, this agent might have a physiological role in the central control of the thermoregulatory 
and cardiovascular systems. 
The rises in blood pressure and heart rate after administration of the smallest dose of PGF 20' 
became apparent earlier than did the increase in the body temperature. It can thus be conc1uded that 
the cardiovascular changes were not a consequence of the hyperthermia. The dose-response curve 
for the hyperthermic effect of PGF2 0' lies within about the same dose range as that for the cardio-
vascular changes, however, so that it cannot be argued that PGF20i is more selective in inducing 
cardiovascular changes than in inducing an increase in the body temperature. It is obvious that the 
cardiovascular and thermal effects of PGF2 0' are due to an activation of the sympathetic nervous 
system (2, 12). The rapid onset of the effects also suggests the involvement of neuronal mechanisms. 
Although indomethacin and sodium mec10fenamate appear to exert their effects mainly by the 
inhibition of prostagIandin biosynthesis (16), sodium mec10fenamate and other fenamates also 
antagonise the effects of exogenous PGF2 0' in some peripheral tissues (8, 9, 10). The present results 
demonstrate that neither peripheral nor central pretreatments with indomethacin or sodium mec1o-
fenamate are able to antagonise the cardiovascular and thermal effects induced by centrally ad-
ministered PGF2 0'. Moreover, peripheral but not central pretreatment with sodium meclofenamate 
augumented the effects of PGF2 0'. It is therefore possible that sodium mec10fenamate potentiated 
the sympathetic activityor other mechanisms in the periphery which mediate the centrally-induced 
effects of PGF 20" Inhibition of prostaglandin synthesis is likely to enhance the release of noradrenaline 
from the sympathetic nerve endings (17). A rise in blood pressure and decreased heat loss with 
subsequent hyperthermia due to vasocontriction could also be expected as the result of inhibition 
of the subcutaneous administration. However, sodium meclofenamate and indomethacin are both 
well absorbed (19) and inhibit effectively the synthesis of prostaglandins even at considerably lower 
doses than those used in the present experiments (20). It thus seems unlikely that the potentiation 
of the central effects of PGF2 0' by sodium meclofenamate could be entirely due to the inhibition of 
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prostagIandin synthesis. At least at the high doses, sodium meclofenamate and indomethacin may 
also inhibit the activity of cycllc nucleotide phosphodiestherases (21). The cycllc AMP/cyclic GMP 
ratio in tissues may be differently affected by indomethaein and sodium meclofenamate, since these 
drugs have different selectivities towards cyclic AMP and cycllc GMP phosphodiesterases (2I). The 
cycHc AMP/cycIic GMP ratio may in turn be important in the control ofblood pressure (22). Further 
studies are needed, however, to elucidate the mechanisms by which sodium meclofenamate potentiates 
the central effects of PGF,,,. 
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